Spastic Paraplegia 21 (SPG21) (N-Term) Peptide
Our Local Distributor
北京 101111
Quick Overview for Spastic Paraplegia 21 (SPG21) (N-Term) Peptide (ABIN5671444)
抗原
宿主
资源
应用范围
-
-
蛋白结构域
- N-Term
-
序列
- GTVPLKKIIV DDDDSKIWSL YDAGPRSIRC PLIFLPPVSG TADVFFRQIL
-
产品特性
- This is a synthetic peptide designed for use in combination with anti- SPG21 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
储存条件
- -20 °C
-
储存方法
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- SPG21 (Spastic Paraplegia 21 (SPG21))
-
背景
-
The protein encoded by this gene binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. Mutations in this gene are associated with autosomal recessive spastic paraplegia 21 (SPG21), also known as mast syndrome. Alternative splicing results in multiple transcript variants.
Alias Symbols: MAST, ACP33, GL010, BM-019
Protein Size: 281 -
基因ID
- 51324
-
NCBI登录号
- NM_001127889, NP_001121361
抗原
-